At a glance
- What the study gets you
- Access to the study treatment being tested
- Type of study
- Interventional (receives a drug or procedure)
- Time in hospital
- In-person visits at study sites — visit count not specified by the sponsor
- Drug or intervention
- Gut hormones (other)
- How long the study runs
- Study runs about 109 months (dates as stated)
- About the drug or intervention
- Gut hormones — other: Their first visit will act as an acclimatisation visit and participants will be infused subcutaneously with a triple gut hormone infusion (GLP-1, PYY and OXM).
- Patient visit burden
- Not specified by the sponsor
- Type of study
- Testing a treatment
- Ages
- 18 Years to 70 Years
- Who
- All
- Number of participants
- 220
- Started
- 2018-08-01
- Last checked
- 2025-05
Plain English Summary
What is this study?
- • Testing a new treatment for bariatric surgery candidate
- • NA - 220 participants
- • Obesity and type 2 diabetes are major causes of illness and premature death worldwide and their incidence is increasing rapidly
Who can take part?
- • Ages 18 Years to 70 Years
- • Diagnosed with bariatric surgery candidate
Where?
- • London - Imperial College London
This is a simplified summary. Always discuss with your doctor before making any decisions.
About This Trial
Obesity and type 2 diabetes are major causes of illness and premature death worldwide and their incidence is increasing rapidly. Bariatric surgery is considered as the "gold-standard" surgical treatment for both conditions. However, not all patients do equally well after surgery and indeed the weight loss experienced by patients undergoing bariatric surgery can vary. As such when patients are seen after bariatric surgery in clinic they fall in one of the following two categories: 1. Good responders: this is the majority of patients who lose the expected amount of weight based on the published studies. 2. Poor responders: this is a small group of patients who either lose less than the expected amount of weight after bariatric surgery or lose the expected amounts of weight early after surgery but then regain a substantial proportion of the weight they have lost. The so-called "poor responders" are exposed to all the risks of the operation and do not benefit from the weight loss as much as good responders. This study would therefore like to investigate the physiological factors that distinguish poor from good responders before, and after bariatric surgery. The study team hypothesizes that compared to good responders, poor responders exhibit: 1. a smaller degree of fullness sensation after a meal, 2. a lower energy expenditure after a meal, and 3. genetic changes (single nucleotide polymorphisms) that predispose the poor responder to development of obesity. In addition, the study team hypothesizes that poor responders exhibit: 1. lower gut hormone secretion after a meal and 2. are less sensitive to the physiological action of gut hormones compared to good responders and that this difference in gut hormone secretion and response to gut hormones prior to bariatric surgery can be helpful to predict response to bariatric surgery.
How this trial compares with your answers
Answer 2 more questions to improve match
What we know so far
Still need:
- • Tell us your age for better matching
- • Tell us your sex for better matching
Preliminary match based on your answers. Full eligibility requires on-site assessment including medical history, physical exam, and lab tests. This does not guarantee enrolment.
Eligibility at a Glance
Key info
- Age: 18 Years - 70 Years
- Who can join: All genders
What the study is looking for
- ✓Aged 18 -70 years.
- ✓Male or female.
- ✓Previous bariatric surgery for obesity and/or diabetes (studies 1 and 2).
- ✓≥1 year interval after bariatric surgery (studies 1 and 2).
- ✓Awaiting bariatric surgery at the Imperial Weight Centre (study 3)
Who cannot take part
- ✗Without access at home to a telephone or other factor likely to interfere with ability to participate reliably in...
- ✗Pregnancy or breastfeeding.
- ✗Unable to maintain adequate contraception for the duration of the study and for one month afterwards.
- ✗History of hypersensitivity to any of the components of the subcutaneous infusions.
- ✗Donated blood during the preceding 3 months or intention to do so before the end of the study.
See the full criteria
Where Is This Study? (1 UK site)
Imperial College London
London W120NN, United Kingdom
How to Get in Touch
Kleopatra Alexiadou, PhD
Sponsor contactCONTACT